Humacyte HUMA
NASDAQ HUMA
$0.59 +0.00 (+0.29%)
At close: Nov 11, 2026 · 4:00 PM EST

Humacyte (HUMA) Gross Margin (2025 - 2026)

Updated

Humacyte's Gross Margin came in at -203.20% for Q2 2026, down 232.44 percentage points from 29.24% a year earlier but up 108.52 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) Gross Margin (2025 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Humacyte reported Gross Margin of -494.58%, down 550.57 percentage points year-over-year; for FY2025, it was -376.05%.

  • The five-year range for quarterly Gross Margin is -1844.75% (Q4 2025) to 71.57% (Q1 2025).
  • Business Quant data shows HUMA's Gross Margin at -311.72% (Q1 2026), -1844.75% (Q4 2025) and 65.47% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 83.88%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 68.12%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 75.38%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 72.95%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 88.03%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 73.10%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 81.07%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 75.71%
10 Humacyte 163.90 Mn -213.24 Mn -401,000.00 -39.01%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -39.01%
Jun 30, 2026 -203.20%
Mar 31, 2026 -311.72%
Dec 31, 2025 -1,844.75%
Sep 30, 2025 65.47%
Jun 30, 2025 29.24%
Mar 31, 2025 71.57%
API Access

Humacyte Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY